Resolve Stroke

Resolve Stroke operates at the intersection of medical imaging, neurodiagnostics, artificial intelligence, and medical devices. Its stated differentiation is a software-defined layer that converts raw ultrasound signals into quantitative biomarkers, rather than positioning ultrasound solely as a conventional imaging modality. The company’s platform focuses on cerebral hemodynamics, microvascular blood flow, large-vessel occlusion assessment, and delayed neurological injury risk. Products such as RS Neuro Suite, RS USP, and RS LVO suggest a modular approach that could support both clinical neuromonitoring and diagnostic workflows, while the SYLVER system provides a more integrated imaging proposition. The company also describes licensing opportunities with ultrasound OEMs and healthcare providers, which could provide an alternative to building a standalone hospital hardware footprint. Resolve Stroke has disclosed five investors and approximately $5.19 million in funding, indicating an early-stage position rather than established market scale.

Resolve Stroke’s trajectory shows a transition from company formation and technical development toward funded clinical-product expansion. Founded on May 2, 2022, it filed or recorded patent activity relating to ultrasound acquisition and processing beginning in 2022 and continuing in 2023. On Sep 18, 2023, the company announced a €2.2 million pre-seed round, approximately $2.35 million, backed by OVNI Capital, Quantonation, Kima Ventures, and Bpifrance. The €2.5 million grant announced on Jun 1, 2025, approximately $2.84 million, was a larger subsequent financing event and brought disclosed funding to approximately $5.19 million. Product breadth is another inflection point: the company lists an integrated SYLVER Ultrasound Imaging System, the RS Neuro Suite software engine, two clinical scoring tools, and a research platform for microvascular dynamics. That breadth suggests parallel development across hardware, imaging software, biomarkers, and research applications. However, there is no disclosed employee-growth series, hiring plan, revenue data, regulatory timeline, or commercial deployment evidence, so the pace from funded development to scaled adoption remains uncertain.